Axo Longevity

Axo Longevity is a membership-based preventive health and performance platform that uses deep biomarker testing to help members understand and extend their healthspan. Members book blood draws at certified partner laboratories, and each comprehensive panel covers 100+ biomarkers spanning cardiovascular, metabolic, hormonal and immune systems, compared with the 10-12 markers of a standard medical test. Results are reviewed by the company's experts rather than by algorithms alone and are returned as an Axo Longevity Health Score, a biological age calculation and a marker-by-marker breakdown benchmarked against optimal ranges rather than standard laboratory reference ranges.

The output is a personalised health blueprint of ranked, actionable interventions across nutrition, sleep, supplementation, exercise and stress, covering more than 36 health areas including sex hormones, cognition, weight and body fat, allergies and dental health. A follow-up panel of targeted biomarkers at the six-month mark is used to check whether interventions are working, making the protocol a repeating measure-decode-act-retest cycle rather than a one-off check-up. Members can also access consultations with a longevity specialist, at-home biomarker testing on request, and discounted advanced tests such as gut, brain, VO2, DEXA, biological age and genetics tests through curated partners. The company states it is building an AI "copilot doctor" that learns continuously from member data.

Protocol design is led by a clinical bench drawn from elite sport: Chief Medical Officer Niko Mihic, MD, medical supervisor at Real Madrid FC and head of NBA research in Europe; Executive Longevity Advisor Andy Walshe, PhD, former head of high performance at Red Bull; and Longevity Advisor Dr. Jorge Planas, medical director of Clínica Planas. Advisors include Mario Schlosser (Oscar Health), Cyrus Massoumi (Zocdoc), Fabian Siegel (Delivery Hero, Marley Spoon), Amol Sarva (Knotel, LifeX Ventures), Eric Solomon, Lisa Kleinsorge and Rosa Hamalainen.

Founding story

The company was started by Andrew McCarthy in response to what he describes as a shift in consumer health from reactive treatment toward proactive prevention, alongside the growth of gyms, supplements, biohacking and wearables into a broader longevity movement. He argues that European public healthcare is limited and reactive, and that Europe trails the United States by roughly twelve months on preventive health adoption, leaving an opening for a clear proactive pathway. The name derives from the axolotl, a Mexican salamander known for regenerating limbs and repairing its body and once close to extinction, chosen as a reference to McCarthy's Mexican roots and as a metaphor for regeneration and extended healthy life; "Longevity" was appended to clarify the category.

Business model

Subscription memberships sold directly to consumers, with testing delivered through third-party certified laboratory partners rather than owned clinics. Payments are processed through Stripe and memberships can be cancelled at any time. The company offers a money-back guarantee if members do not receive meaningful insights.

Annual membership tiers billed yearly: Axo Longevity Lite at EUR 190 per year (approximately EUR 16 per month) for 50+ biomarkers in a single round; Axo Longevity Care at EUR 490 per year (approximately EUR 41 per month) for 100+ biomarkers across two rounds plus sports science protocols, a personalised blueprint and continuous tracking; and Axo Elite at EUR 5,000 per year (approximately EUR 417 per month) adding 150+ biomarkers across two rounds, a 1:1 longevity session with Dr. Niko Mihic or Andy Walshe, GlycanAge testing, comprehensive genome testing and an annual founding member event. Consultations with a longevity specialist and at-home testing are available on request, and advanced third-party tests are offered at a discount through partners.

Traction

Around 250 blood-draw locations via lab partners (the website cites more than 1,000 locations across Europe and, in one place, more than 1,450 certified partner labs), operations across six countries, a completed private beta with paying customers and ambassadors, and a waitlist of approximately 10,000 people.

Latest developments

Everywhere Ventures published a founder profile of CEO Andrew McCarthy in January 2026 and a company spotlight in February 2026, describing membership operations across four European markets, the AI copilot doctor in development, and exploration of Latin American expansion.